MSN Laboratories will be unable to move forward – for now – with any potential ‘at-risk' launch for its generic version of Novartis' Entresto blockbuster in the US after the originator won a stay on the firm's ANDA pending appeal from the US Court of Appeals For the District of Columbia Circuit.
Dean Rudge is a journalist whose work has appeared in Informa. He focuses on the pharmaceutical and biotech industries, covering topics such as biosimilars, drug launches, legal disputes, and market trends. With a keen interest in the healthcare sector, Dean provides insightful analysis and reporting on key developments in the industry.